ProShares Ultra Nasdaq Biotechnology (BIB)

Add to Watchlists
Create an Alert
93.87 -2.81  -2.91% NASDAQ Jul 29, 17:00 Delayed 2m USD
View Full Chart
BIB Price Chart

BIB Description

ProShares Ultra Nasdaq Biotechnology is a long-short equity fund managed by ProShares that tracks the NASDAQ Biotechnology TR USD index and has 924.96M USD assets under management. It has an forecasted dividend yield of 0.22%, a forecasted PE ratio of 27.02, and a forecasted price to book value of 7.305. The fund has a net expense ratio of 0.95%, turns over its positions 26.00% per year, and is traded on the NASDAQ.

BIB Key Info

Expense Ratio (1-9-15) 0.95%
Assets Under Management (7-27-15) 924.96M
30-Day Average Volume (7-28-15) 770438.3
Net Asset Value (7-27-15) 92.04
Discount or Premium to NAV (7-28-15) 0.24%
Turnover Ratio (5-31-14) 26.00%

BIB Asset Allocation

Type % Net % Long % Short
Cash -96.38% 38.48% 134.9%
Stock 152.9% 156.6% 3.74%
Bond 0.00% 0.00% 0.00%
Convertible 0.00% 0.00% 0.00%
Preferred 0.00% 0.00% 0.00%
Other 43.50% 43.50% 0.00%
As of June 30, 2015

BIB Region Exposure

Americas 97.27%
North America 97.27%
Latin America 0.00%
Greater Europe 2.69%
United Kingdom 1.92%
Europe Developed 0.72%
Europe Emerging 0.00%
Africa/Middle East 0.05%
Greater Asia 0.04%
Japan 0.00%
Australasia 0.00%
Asia Developed 0.00%
Asia Emerging 0.04%
Market Classification
% Developed Markets 99.96%
% Emerging Markets 0.04%
As of June 30, 2015
Region breakdown data is calculated by using the long position holdings of the portfolio.

BIB Stock Sector Exposure

Basic Materials 0.00%
Communication Services 0.00%
Consumer Cyclical 0.00%
Consumer Defensive 0.00%
Energy 0.00%
Financial Services 0.00%
Healthcare 0.00%
Industrials 0.00%
Real Estate 0.00%
Technology 0.00%
Utilities 0.00%
As of June 30, 2015

BIB Stock Market Capitalization

Giant --
Large --
Medium --
Small --
Micro --
As of June 30, 2015
View More Holdings

BIB Top 10 Holdings

Name % Weight Price % Chg
Nasdaq Biotechnology Index Swap Credit Suisse International 67.07% -- --
Ishares Biotech (Ibb) Swap Morgan Stanley & Co. International Plc 27.88% -- --
Ishares Biotech (Ibb) Swap Deutsche Bank Ag 8.89% -- --
Nasdaq Biotechnology Index Swap Ubs Ag 7.64% -- --
Nasdaq Biotechnology Index Swap Bank Of America, Na 5.76% -- --
Ishares Biotech (Ibb) Swap Bank Of America, Na 5.10% -- --
Gilead Sciences Inc 5.07% 115.70 +2.33%
Biogen Inc 4.95% 313.44 -2.03%
Celgene Corp 4.92% 132.08 -2.47%
Amgen Inc 4.78% 171.47 -0.74%
As of June 30, 2015
Advertisement

BIB Basic Info

Style
Equity Style Large Cap/Growth
Broad Asset Class Alternative
Broad Category Alternative
Prospectus Objective Specialty - Health
Fund Owner Firm Name ProShares
Benchmark Index
NASDAQ Biotechnology TR USD 200.0%

BIB Manager Info

Name Tenure
Charles Lowery 1.75 yrs
Michael Neches 1.75 yrs

BIB Risk Info

Beta 1.689
Max Drawdown (All) 41.44%
Historical Sharpe (10y) --
Historical Sortino (All) 3.501
30-Day Rolling Volatility 51.39%
Daily Value at Risk (VaR) 1% (All) 7.69%
Monthly Value at Risk (VaR) 1% (All) 30.77%

BIB Fundamentals

Dividend Yield TTM (7-29-15) 0%
Weighted Average PE Ratio --
Weighted Average Price to Sales Ratio --
Weighted Average Price to Book Ratio --
Weighted Median ROE --
Weighted Median ROA --
Forecasted Dividend Yield 0.22%
Forecasted PE Ratio 27.02
Forecasted Price to Sales Ratio 8.320
Forecasted Price to Book Ratio 7.305
Number of Holdings 168
As of June 30, 2015

BIB Growth Estimates

Forecasted 5 Yr Earnings Growth 13.60%
Forecasted Book Value Growth 13.40%
Forecasted Cash Flow Growth 30.02%
Forecasted Earnings Growth 36.58%
Forecasted Revenue Growth 15.23%
As of June 30, 2015

BIB Performance

  Returns Total Returns
1M 1.79% 1.79%
3M 18.15% 18.15%
6M 36.15% 36.15%
1Y 111.4% 111.4%
3Y 536.4% 536.4%
5Y 1611% 1634%
As of July 27, 2015

BIB Net Flows

1M -90.62M
3M -29.29M
6M 106.78M
YTD 106.78M
1Y 170.34M
3Y 370.46M
5Y 388.71M
As of June 30, 2015

BIB Attributes

Key Dates
Inception Date 4/6/2010
Last Annual Report Date 5/31/2014
Last Prospectus Date 1/9/2015
Attributes
Exchange Traded Share Yes
Exchange Traded Note No
Enhanced Index Fund No
Index Fund Yes
Inverse Fund No
Leveraged Fund Yes
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
General Availability
Available for Insurance Product No
Available for Retirement Plan No
Available for RRSP No
Advertisement

You've hit the 10 page limit on YCharts.

Experience the power of YCharts.
Start your Free 7-Day Trial.

Start My Free Trial No credit card required.

Already a subscriber? Sign in.

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}
Start your free 7-Day Trial.

{{root.upsell.info.button_text}} No credit card required.

Already a subscriber? Sign in.